D.Phil in Paediatrics
B.Sc. in Neuroscience
Awards & Fellowships
SRF-CASMI-Oxford Alliance Fellowship // Oxford
National Institute for Health Research // Oxford
Distinguished Presidential Achievement Scholar // University of Texas at Austin
International Education Scholarship // University of Texas at Austin
Undergraduate Research Fellowship // University of Texas at Austin
Phi Kappa Phi Honor Society // University of Texas at Austin
Swedish Excellence Endowment // Swedish-American Alliance
--- Published ----
Halioua-Haubold C, Brindley DA, Arshad Z, Smith JA. Regulation of Cell-based Medicinal Products. International Fundamentals of Regulatory Affairs. Regulatory Affairs Professionals Society; 2017. (link to book on Amazon)
Arshad Z, Halioua-Haubold C, Smith JA, Roberts M, Brindley DA, Brandford O, Baiarda FU, Pettitt D. Adipose Stem Cells in Aesthetic Surgery: A Snapshot of the Current Clinical Trials Landscape, Translational Barriers, and Clinical Adoption. Aesthetic Surgery Journal. 2017:1-12.
Halioua-Haubold C, Peyer J, Smith JA, Arshad Z, Scholz M, Brindley DA, and MacLaren RE. Regulatory Considerations for Gene Therapeutics in the US, EU, and Japan. Yale J. Biol Med. 2017(90):683-93.
--- Submitted ---
Halioua-Haubold C, Jolly JK, Smith JA Pinedo-Villanueva R, Brindley DA, and MacLaren RE Potential Lifetime Quality of Life Benefits of Choroideremia Gene Therapy: Projections from a Clinically Informed Decision Model. Accepted pending minor revisions, Eye
Halioua-Haubold C, Meinert E, Pinedo-Villanueva R, MacLaren RE, and Brindley DA. Health Economic Analyses of Gene Therapies: A Systematic Review Protocol. In Peer Review, Systematic Reviews
Halioua-Haubold C, MacLaren RE, de Keizer P. Clinical Translation of Peptide Therapeutics: Promising Applications in Aging. Invited Review, Mechanisms of Ageing & Development
Artificial Intelligence to Predict Periprosthetic Joint Infection after Total Hip Replacement Bone and Joint Research
Halioua-Haubold C and Brindley DA. Chimeric Antigen Receptor Mediated Immunotherapy for Glioblastoma Multiforme. (Chapter in a yet untitled book in publication with Elsevier)
--- In Progress ---
Halioua-Haubold C, Brindley DA, MacLaren RE, and Pinedo-Villanueva R. Preventative Gene Therapeutics Can Deliver Significant Patient Benefit, but Payer Adoption Challenges Loom Submitting to Health Affairs
A Systematic Review of Gene Therapy Economic Analyses
Evaluating existing economic analyses of cell and gene therapies to understand and define methodology, strengths and weaknesses within and inform development of ocular economic models.
Cost-Effectiveness of Choroideremia Gene Therapy Adoption in the United Kingdom
Using previously developed and validated choroideremia gene therapy patient benefit model to determine the potential cost-effectiveness of choroideremia gene therapy in the NHS healthcare system.
Developing a Vaccine for Herpes Virus: US Healthcare Implications
Using Markov modeling to develop a model of herpes simplex virus I and II infection risk and patient outcomes, and the benefit of a prophylactic vaccine candidate on patient quality of life and US healthcare system.
Oxford Ophthalmological Conference July 2018
“A dual variable Markov model to assess the potential benefits of choroideremia gene therapy on quality adjusted life years (QALYs)”
ARVO Ophthalmology Annual Meeting April 2018
“A dual variable Markov model to assess the potential benefits of choroideremia gene therapy on
quality adjusted life years (QALYs)”
CellGene Meeting on the Mesa October 2017
“The Impact of Curative Therapies for Orphan Indications: A Case Study of Choroideremia Gene Therapy"
Fall Undergraduate Research Symposium October 2016
“A Bacterial-Derived Method for Treating Enteric Neuropathy”
Rejuvenation Biotechnology Conference August 2016
“A Bacterial-Derived Method to Deliver Therapeutics to Enteric System Neurons”
Naturvetarkonferensen October 2015
“Development of a Bacterial-Honed Transfection Method”
Rejuvenation Biotechnology Conference August 2015
“A Novel Transfection Method in Patient-Derived Glioblastoma Cells”
Sanford Burnham Prebys Medical Discovery Institute // La Jolla, California USA // Dr. Evan Snyder
Designing Better Therapeutics for the Enteric Nervous System
Worked extensively with patient derived glioblastoma cell lines and murine stem-like cell lines. Independently piloted a new project in the laboratory investigating the transfection dynamics and potential translational viability of a bacterially derived neuronal-targeting protein.
The University of Texas at Austin // Austin, Texas USA // Dr. Richard Morrisett
Exploring the Neuropharmacology of Alcohol Addiction
Tested the biocompatibility and uptake of a novel neuronal tracer for use in in vivo mouse experiments.
Assisted with the development and investigation of a mouse model of alcohol dependency. Investigated the changes to the dopaminergic reward pathway.
The University of Texas at Austin // Austin, Texas USA // Dr. Keith Stevenson
Designing Novel Fluorescent Nanoparticle-Based Neuronal Tracers
Synthesized DNA-templated silver nanoclusters (Ag-NCs) and super-paramagnetic iron oxide nanoparticles. Experimented with Ag-NC formulation and design to improve fluorescence duration and wavelength.